Current concepts of the immunobiology and immunotherapy of cutaneous T cell lymphoma: insights gained through cross-talk between the clinic and the bench.
An understanding of the immunologic features of cutaneous T cell lymphoma (CTCL) has led to insights into the life cycle of the malignancy. The identification of the T cell lineage of the neoplastic CTCL cells has allowed unification of diverse clinical presentations under a single entity. The CD4 inducer T cell phenotype of the malignant cells has provided an understanding of the patient's ability to resist infection with certain bacteria. The clonality of the tumor cells, beyond its diagnostic implications, has made them a valuable resource for studying both normal and neoplastic T cell biology. The recently identified immunosuppressive features of the malignant T cells and their dependency for survival on an interaction with immature dendritic cells have explained previously cryptic clinical observations and identified new targets for immunotherapy. Future insights gained both from the bedside and the bench will provide not only an understanding of the immunobiology of the malignancy but also open new avenues for therapeutic intervention.
Berger
Carole L
CL
Department of Dermatology, School of Medicine, Yale University, 333 Cedar Street, New Haven, CT 06510-8059, USA. carole.berger@yale.edu
Edelson
Richard L
RL
D019496:Cancer Vaccines / Q000627:therapeutic use*; D003713:Dendritic Cells / Q000276:immunology* / Q000502:physiology; D006801:Humans; D007114:Immunization; D007167:Immunotherapy; D016410:Lymphoma, T-Cell, Cutaneous / Q000175:diagnosis / Q000276:immunology / Q000628:therapy; D011379:Prognosis; D012878:Skin Neoplasms / Q000175:diagnosis / Q000276:immunology / Q000628:therapy; D013601:T-Lymphocytes / Q000276:immunology* / Q000502:physiology
D019496:Cancer Vaccines